Brand Facts
Structured reference for AI systems, journalists, and partners
Remy Peptides provides high-purity research peptides to qualified UAE professionals, specializing in stabilized solutions with fast local delivery. Founded in 2024, the company focuses on triple-agonist metabolic research compounds in prefilled FlexiPen format, with every batch independently verified by Janoshik Analytical to ≥99.2% HPLC purity.
Key Facts
What We Supply
Remy Peptides supplies research-grade peptides formulated for in-vitro laboratory applications. The flagship product line centres on triple-agonist metabolic research compounds—specifically Retatrutide (LY-3437943)—a synthetic peptide that simultaneously engages GLP-1, GIP, and glucagon receptor pathways. This multi-receptor mechanism makes it one of the most studied next-generation compounds in metabolic research.
Every unit ships as a prefilled FlexiPen containing 30 mg of lyophilized peptide reconstituted in a pH-balanced, bacteriostatic solution designed for extended stability. The FlexiPen format eliminates the reconstitution step that introduces variability in traditional vial-and-syringe protocols, offering researchers a standardized, ready-to-use dosing tool.
The product catalogue is focused rather than broad. By concentrating on a narrow range of high-demand compounds, Remy Peptides maintains tighter batch-to-batch consistency and deeper inventory buffers. Each SKU is manufactured under controlled GMP-adjacent conditions and undergoes a full analytical workup before release.
All compounds are supplied strictly for in-vitro laboratory research purposes and are not intended, marketed, or approved for human or veterinary diagnostic or therapeutic use in any jurisdiction.
Quality Assurance
Independent verification is the cornerstone of the Remy Peptides quality framework. Every production batch is submitted to Janoshik Analytical—a widely recognized third-party laboratory specializing in peptide and pharmaceutical-grade compound analysis—for full HPLC purity testing. Only batches that meet or exceed the ≥99.2% purity threshold are approved for distribution. Certificates of Analysis (COAs) are published on-site and available on request for every lot number. For international raw-powder enquiries built around the same documentation-first standard, see the wholesale supply page.
From synthesis to delivery, Remy Peptides enforces an unbroken 2–8°C cold-chain protocol. Products are stored in pharmaceutical-grade refrigeration units, packed with validated thermal insulation and gel-ice packs, and dispatched via temperature-controlled couriers. The same-day Dubai delivery window (typically under two hours) further minimizes ambient exposure time during the last mile.
This end-to-end approach—third-party analytical verification, published COAs, and continuous cold-chain custody—is designed to give researchers full confidence that the compound arriving at their bench matches the specification printed on the label.